Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

FOLFIRINOX: a small step or a great leap forward?

Ko AH.

J Clin Oncol. 2011 Oct 1;29(28):3727-9. doi: 10.1200/JCO.2011.37.3464. Epub 2011 Sep 6. No abstract available.

PMID:
21900100
2.

FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.

Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D.

Expert Rev Anticancer Ther. 2014 Oct;14(10):1115-25. doi: 10.1586/14737140.2014.957188. Epub 2014 Sep 10. Review.

PMID:
25204327
3.

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M.

Curr Oncol Rep. 2013 Apr;15(2):182-9. doi: 10.1007/s11912-012-0290-4. Review.

PMID:
23341367
4.

[Chemotherapy for colon cancer].

Sasaki E, Maeda Y, Sasaki T.

Nihon Rinsho. 2003 Sep;61 Suppl 7:298-302. Review. Japanese. No abstract available.

PMID:
14574899
5.

Adjuvant therapy in colon cancer: which treatment in 2005?

Di Costanzo F, Doni L.

Ann Oncol. 2005 May;16 Suppl 4:iv69-73. Review. No abstract available.

PMID:
15923433
6.

Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.

Fisher MD.

Clin Colorectal Cancer. 2001 Aug;1(2):82-4. Review. No abstract available.

PMID:
12445364
7.

What options are available for refractory pancreatic cancer?

Choi M, Kim R, Saif MW.

JOP. 2012 Mar 10;13(2):163-5. Review.

8.

[Standard chemotherapy for colonic neoplasms].

Hyodo I.

Nihon Naika Gakkai Zasshi. 2007 Feb 10;96(2):283-8. Review. Japanese. No abstract available.

PMID:
17370594
9.

Locally advanced pancreatic cancer.

Oikonomopoulos GM, Huber KE, Syrigos KN, Saif MW.

JOP. 2013 Mar 10;14(2):126-8. doi: 10.6092/1590-8577/1469. Review.

10.

[Present status of chemotherapy for colorectal cancer in countries outside of Japan].

Doi T, Ohtsu A.

Nihon Rinsho. 2003 Sep;61 Suppl 7:368-73. Review. Japanese. No abstract available.

PMID:
14574915
11.

FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S; Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD).

Pancreas. 2015 May;44(4):515-21. doi: 10.1097/MPA.0000000000000314. Review.

PMID:
25872127
12.

[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].

Shimoyama S, Kondo K, Kataoka M.

Nihon Rinsho. 2003 Sep;61 Suppl 7:356-9. Review. Japanese. No abstract available.

PMID:
14574912
13.

[Gemcitabine-based combinations in inoperable pancreatic cancers].

Louvet C, André T, Artru P.

Bull Cancer. 2002 Aug;89 Spec No:S96-101. Review. French.

14.

Pancreatic cancer and FOLFIRINOX: a new era and new questions.

Marsh Rde W, Talamonti MS, Katz MH, Herman JM.

Cancer Med. 2015 Jun;4(6):853-63. doi: 10.1002/cam4.433. Epub 2015 Feb 19. Review.

15.

Evolution of systemic therapy for metastatic colorectal cancer.

Geh JI, Ma YT.

Colorectal Dis. 2011 Aug;13(8):852-4. doi: 10.1111/j.1463-1318.2011.02710.x. Review. No abstract available.

PMID:
21762349
16.

Update on capecitabine alone and in combination regimens in colorectal cancer patients.

Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S46-55. doi: 10.1016/S0305-7372(10)70020-7. Review.

PMID:
21129610
17.

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.

Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E.

World J Gastroenterol. 2016 Aug 21;22(31):6987-7005. doi: 10.3748/wjg.v22.i31.6987. Review.

18.

Common side effects and interactions of colorectal cancer therapeutic agents.

Holt K.

J Pract Nurs. 2011 Spring;61(1):7-20. Review. No abstract available.

PMID:
21751717
19.
20.

Supplemental Content

Support Center